| Sarah Jerge, PA-C | |
|
2142 N Cove Blvd, Toledo, OH 43606-3896 | |
| (419) 291-4000 | |
| Not Available |
| Full Name | Sarah Jerge |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 2142 N Cove Blvd, Toledo, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043786577 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 50.005924RX (Ohio) | Primary |
| 363A00000X | Physician Assistant | PA6804 (Massachusetts) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Jerge, PA-C 333 N Summit St Fl 7, Toledo, OH 43604-1531 Ph: () - | Sarah Jerge, PA-C 2142 N Cove Blvd, Toledo, OH 43606-3896 Ph: (419) 291-4000 |
News Archive
Shina Systems announces U.S. Federal Food and Drug Administration (FDA) 510(k) clearance for its 3Di medical imaging advanced (3D/4D) visualization software that downloads over the Internet and provides a full suite of image processing and clinical analysis applications on any PC.
Nonalcoholic fatty liver disease (NAFLD) is often caused by abdominal obesity, which is also one of the main causes of insulin resistance and metabolic syndrome. The latter, in turn, is an important cardiovascular risk factor, and has been found to be associated with the presence of carotid atherosclerotic lesions.
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
Researchers from New York Institute of Technology have secured $426,621 in funding from the National Science Foundation for the acquisition of a micro-computed tomography machine.
Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in preclinical models in contrast to existing GABAA receptor non-selective agonists, such as benzodiazepines.
› Verified 1 days ago
Stephen P Kyser, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 2940 N Mccord Rd, Toledo, OH 43615 Phone: 419-842-3000 Fax: 419-824-3042 | |
Bailey Jameson, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 2221 Madison Ave, Toledo, OH 43604 Phone: 419-251-1313 | |
Nichole A Hubbard, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-291-5318 Fax: 419-291-6430 | |
Timothy Michael Tabor, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1415 Jefferson Ave, Toledo, OH 43604 Phone: 419-255-7883 | |
Kelly M Sadowski, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 301 Morrison Dr, Toledo, OH 43605 Phone: 567-218-0770 | |
Brent Alexander Bernard, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 4405 North Holland Sylvania Rd, Toledo, OH 43623 Phone: 419-517-0146 Fax: 419-517-0147 | |
Alison Fleig, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3830 Woodley Rd Ste 2a, Toledo, OH 43606 Phone: 419-724-0004 |